Business Wire

PPG Experts to Showcase Future of Automotive Color Styling, Application Technology at Surcar Europe 2021

1.7.2021 16:02:00 EEST | Business Wire | Press release

Share

PPG (NYSE: PPG) today announced that its experts will share the future of sustainable automotive color styling and application technology in presentations at the Surcar Europe 2021 automotive engineering and design show, which is being held this week in Cannes, France.

Sabine Griesbeck, PPG digital transformation technical manager, will discuss the future of color development using digital color styling. A presentation by Sven Reil, PPG automotive application manager, Europe, Middle East and Africa, will cover paint as an enabler for precision application. Both presentations will be given on July 1.

PPG’s digital styling program will enable automotive designers to execute exceptionally realistic three-dimensional modeling of automotive colors and effects on virtual car designs and surfaces, significantly speeding up the process of developing new colors and reducing waste.

“Prior to the development of PPG's digital color styling program, the time taken from the designer’s vision to a final color could be as long as nine months,” said Griesbeck. “The color team developed several different variations of a color. These are then applied to test panels that are sent to the customer for review. This generated waste, and having small panels does not give a good real-world representation of the color.”

PPG’s digital styling library features a proprietary “speed shape” that accurately depicts the interaction of color, geometry and light. It also offers the option to download digital color files that are fully compatible with industry-standard color-rendering software. This enables design teams to collaborate with PPG experts directly, remotely and in real time.

“This is the first step in fully digitizing the entire color styling process for PPG customers,” Griesbeck said. “Imagine if in the future you can adjust a color virtually according to your wishes, and the new color design is digitally born and ready to use in production. There are also significant sustainability benefits, as we expect this new way of working will reduce the carbon dioxide (CO2) footprint through lower material and energy consumption.”

Individualization and customization are also leading to an increased demand for two-tone schemes. PPG’s breakthrough precision application technology for automotive coatings significantly streamlines the painting of these schemes, producing crisp paint edges without the use of masking and other time-intensive steps currently required to achieve a two-tone finish.

“The conventional process requires that a vehicle be fully painted before paint shop personnel mask off areas that will not receive the second color,” said Reil. “The vehicle must then be run through the paint line or a repair line a second time to apply the contrasting color. In addition to reducing paint shop capacity, this second run can add significant material, labor and energy costs to the total unit cost of the vehicle.”

The precision process uses a specially designed PPG coating as well as innovative application heads that apply the paint directly without overspray. This can reduce paint shop time by approximately 50 minutes per two-tone vehicle. This process also advances customer sustainability goals by reducing CO2 emissions and eliminating energy-intensive air-filtering systems that handle overspray from the paint application process, reducing costs and improving efficiency.

“The process uses a direct printing approach rather than conventional spraying, eliminating overspray and masking,” Reil said. “It allows the application of coatings in an extremely precise manner, giving the ability to combine both sustainability and customization. In the future, complete cars might be painted using precision application technology, offering manufacturers even more options to enhance the appeal of their vehicle models.”

PPG: WE PROTECT AND BEAUTIFY THE WORLD™

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for more than 135 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $13.8 billion in 2020. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

We protect and beautify the world is a trademark and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.

CATEGORY Automotive OEM Coatings

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PPG Media Contacts:
Andrew Wood
Corporate Communications, EMEA
+31 6 5121 6579
awood@ppg.com

Keith Rigby
Automotive OEM Coatings
+1 412-434-1718
krigby@ppg.com
www.ppg.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye